Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

BACKGROUND: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer's disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detai...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Farlow, Martin, Veloso, Felix, Moline, Margaret, Yardley, Jane, Brand-Schieber, Elimor, Bibbiani, Francesco, Zou, Heng, Hsu, Timothy, Satlin, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2011
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126705/
https://ncbi.nlm.nih.gov/pubmed/21612646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-11-57
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados